Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Citius Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Citius Oncology, Inc.’s stock price such as:

• Citius Oncology, Inc.’s current stock price and volume
• Why Citius Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for CTOR from analysts
• CTOR’s stock price momentum as measured by its relative strength

About Citius Oncology, Inc. (CTOR)

Before we jump into Citius Oncology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Want to learn more about Citius Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Citius Oncology, Inc..

Citius Oncology, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Citius Oncology, Inc.’s stock price was $0.592.

Citius Oncology, Inc. is up 3.22% from its previous closing price of $0.574.

During the last market session, Citius Oncology, Inc.’s stock traded between $0.587 and $0.600. Currently, there are approximately 100.03 million shares outstanding for Citius Oncology, Inc..

Citius Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Citius Oncology, Inc. Stock Price History

Citius Oncology, Inc.’s (CTOR) price is currently down 8.89% so far this month.

During the month of July, Citius Oncology, Inc.’s stock price has reached a high of $0.730 and a low of $0.513.

Over the last year, Citius Oncology, Inc. has hit prices as high as $2.310 and as low as $0.491. Year to date, Citius Oncology, Inc.’s stock is down 40.77%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Citius Oncology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Citius Oncology, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Citius Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Citius Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Citius Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Citius Oncology, Inc. (CTOR) by visiting AAII Stock Evaluator.

Relative Price Strength of Citius Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Citius Oncology, Inc. has a weighted four-quarter relative price strength of -32.10%, which translates to a Momentum Score of 6 and is considered to be Very Weak.

Want to learn more about how Citius Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Citius Oncology, Inc. Stock Price: Bottom Line

As of July 31, 2026, Citius Oncology, Inc.’s stock price is $0.592, which is up 3.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Citius Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.